Chronic liver disease is an increasingly prevalent and heterogeneous syndrome with important consequences for cardiovascular ...

Additional Analyses from ACACIA-HCM Further Characterize Exercise Performance, Treatment Effect, Dose Titration and Safety of Aficamten in Non-Obstructive HCM ...

However, it is in the approach to anticoagulation of AF in which the divergence from the conventional thrombotic ...

Enrollment of the first patient in Europe represents continued progress in the global execution of ReVeRA-301 as we advance our pivotal Phase 3 program,” said David Bharucha, M.D., PhD, FACC, Chief ...

Updated clinical practice guidelines outline new protocols for cardiovascular risk assessment and medical therapy prior to noncardiac surgery.

Sometimes surgery can trigger arrhythmias, making it necessary to have a pacemaker or defibrillator fitted: what to do and how to monitor the situation ...

ROI opportunities center on PFA catheters and atrial fibrillation, with differentiation driven by AI-enabled mapping, clinical evidence, training and strategic partnershipsDublin, Oct. 05, 2026 (GLOBE ...

Background Heart failure (HF) remains associated with high mortality worldwide despite advances in guideline-directed therapy ...

Background Atrial fibrillation (AF) is a common cause of ischaemic stroke and a major global health burden, but is often ...

Many patients with atrial fibrillation (AFib) are not receiving any therapy to prevent stroke, and Geoffrey Barnes, MD, ...

U.S. Food and Drug Administration Approves Expanded Indication for Bristol Myers Squibb’s CAMZYOS® (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardio ...

Cytokinetics launched a study assessing the real-world safety and effectiveness of MYQORZO in patients with obstructive ...